Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
Houston, TX – December 17, 2020 – Moleculin Biotech, Inc., (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the company’s Investigational New Drug (IND) application to study […]
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
Houston, TX – December 3, 2020 – Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will present animal data demonstrating highly improved activity against acute myeloid leukemia (“AML”) in combination with the […]
Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066
Priority Review Vouchers subject to approved NDA Houston, TX – December 1, 2020 – Moleculin Biotech, Inc., (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has approved its […]
Moleculin Announces New Data Demonstrating Synergistic Antitumor Activity of Annamycin Combination with Ara-C in AML
Experimental data to be presented at American Society for Hematology Annual Conference Houston, TX – November 19, 2020 – Moleculin Biotech, Inc., (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that new animal data has shown […]
Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial
Adult brain tumor trial advances to final dose escalation cohort of WP1066 Houston, TX – October 13, 2020 – Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced additional preliminary […]
Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University
WP1066 demonstrates activity in DIPG, rare form of pediatric brain tumor Houston, TX – October 1, 2020 — Moleculin Biotech, Inc., (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary first cohort […]
Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%
Independent research shows 2-DG activity against virus that causes COVID-19 Houston, TX – April 8, 2020 – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that […]
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
Testing of drug candidate WP1122 to be done by leading Government funded research institution specializing in infectious diseases including COVID-19 Vancouver, BC – March 24, 2020 – WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces it has entered into a development agreement (the “Agreement”) with CNS […]
Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, including Coronavirus
Independent research suggests new approach to inhibiting the viral replication capability of a range of viruses, including Coronavirus Houston, TX – March 17, 2020 – Moleculin Biotech, Inc. (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that it has […]
Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial
Following Successful Completion of US Phase 1 Trial Houston, TX – February 5, 2020 — Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it intends to discuss with the FDA and EMA (European Medicines Agency) […]
